Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | ||
Camzyos | mavacamten | Obstructive hypertrophic cardiomyopathy | Reimburse with clinical criteria and/or conditions | Complete | ||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Sotyktu | deucravacitinib | Psoriasis, moderate to severe plaque | Do not reimburse | Complete | ||
Tavneos | avacopan | Antineutrophil cytoplasmic antibody-associated vasculitis | Do not reimburse | Complete | ||
Verquvo | vericiguat | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Sohonos | palovarotene | Fibrodysplasia Ossificans Progressiva | Reimburse with clinical criteria and/or conditions | Complete | ||
TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete |